Forte Biosciences Inc (FBRX) Stock Forecast & Price Target
Forte Biosciences Inc · NASDAQ
$76.68+0.18 (+0.24%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Forte Biosciences Inc, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $65.00 to $74.00, so the covering firms are broadly aligned. The average target of $69.50 sits 9% below the current $76.68. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.96 next quarter toward $-4.10 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Moderate Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Forte Biosciences Inc.
As of Jul, 4 of 4 firms rate FBRX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
FBRX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.96
Range $-1.16 – $-0.77 · 5 analysts · -3% YoY
Next period, 5 analysts expect Forte Biosciences Inc to earn $-0.96 a share (range $-1.16 – $-0.77), versus $-0.99 a year earlier. Full-year consensus is $-3.89, growing to $-4.10 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 5 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Forte Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on FBRX.
#1
Yatin Suneja
Guggenheim · Rank #28
Buy
$75.00-2.2% to target
Overall win rate
52%
+ Follow
#2
Daniil Gataulin
Chardan Capital · Rank #36
Buy
$61.00-20.4% to target
Overall win rate
55%
+ Follow
#3
GC
Gavin Clark-Gartner
Evercore ISI Group
Buy
$65.00-15.2% to target
Coverage
—
+ Follow
#4
Etzer Darout
Barclays
Buy
$74.00-3.5% to target
Coverage
—
+ Follow
#5
KR
Kumaraguru Raja
Brookline Capital Markets
Buy
$54.00-29.6% to target
Coverage
—
+ Follow
FBRX stock forecast FAQ
What is FBRX's average 12-month price target?+
The 2 analysts with a live target average $69.50 for Forte Biosciences Inc over the next 12 months, ranging from a $74.00 high to a $65.00 low.
Is FBRX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for FBRX?+
The Street-high target is $74.00 (Barclays), and the Street-low is $65.00 (Evercore ISI Group). The average of all 2 active targets is $69.50.
How many Wall Street analysts cover FBRX?+
4 analysts have an active rating on Forte Biosciences Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering FBRX?+
Among analysts who currently cover FBRX, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #28). Their current call is Buy with a $75.00 target.
What is Forte Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is $-0.96 per share (range $-1.16 – $-0.77) across 5 analysts. Full-year EPS is projected at $-3.89, rising to $-4.10 the following year.
How much revenue is Forte Biosciences Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading FBRX lately?+
As of Jul, 4 of 4 firms rate FBRX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their FBRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
